Gemcitabine/carboplatin combination regimens: importance of dose schedule.

Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer

Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy in elderly patients with non-small cell lung cancer. Methods: Seventy-four patients (GC regimen, n = 44; PC regimen, n = 30) received gemcitabine at a dose of 1000 mg/m2 on days 1 and 8, and carboplatin ...

Low-dose Gemcitabine and Carboplatin as a Good Palliation for Local Symptoms in Advanced Transitional Cell Carcinoma of Bladder

Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small- Cell Lung Carcinoma: Phase I/II Study of 28-Day Schedule

Carboplatin plus gemcitabine is a standard regimen for advanced non-smallcell lung carcinoma (NSCLC) but has been frequently accompanied by signifi cant hematologic toxicities. A 28-day schedule of this combination was evaluated in the phase I/II study. For NSCLC patients who were chemotherapy-naïve and having stage IIIB/ IV disease, a fi xed dose of gemcitabine (1,000 mg/m2) was administered o...

Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.

Standard first-line chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC) include carboplatin (Paraplatin)/paclitaxel, cisplatin/docetaxel (Taxotere), cisplatin/gemcitabine (Gemzar), and cisplatin/vinorelbine (Navelbine). An informal meta-analysis of 13 randomized trials of these regimens in NSCLC indicates no marked differences in terms of response rates or survival, but toxicit...

Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non-Small Cell Lung Cancer

Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy administered as an adjuvant therapy after complete resection of non-small cell lung cancer. Methods: Forty-four patients (GC regimen, n = 29; PC regimen, n = 15) received gemcitabine at a dose of 1000 mg...